US regulators have approved the country’s first presbyopia eye drop that adopts pupil constriction to improve near and intermediate vision while maintaining some pupillary response to different lighting conditions.
Read More
Glaukos pens new deal for Preserflo MicroShunt
Glaukos has signed a new license agreement with Santen Pharmaceutical for the Preserflo MicroShunt, obtaining exclusive rights for the therapy in Australia, New Zealand and other territories.
Read More
Read More